ERFURT, Germany and BERLIN and VORARLBERG, Austria, May 12, 2021 /CNW/ – AMP Alternative Medical Products Inc. (Frankfurt: C4TA) (ISIN: CA0318961038) (CSE: XCX), a pharmaceutical supplier of medical cannabis products to German pharmacies and Dr. Feurstein Medical Hemp GmbH (“HANAFSAN”), an Austrian pharmaceutical CBD hemp producer have entered into a supply agreement to import and sell HANAFSAN branded certified CBD Hemp cosmetics in Germany.
AMP will import a range of pharmaceutical grade CBD cosmetics under the HANAFSAN brand name for sale in Germany. These cosmetics are produced from hemp organically cultivated in Europe and processed and manufactured at their EU-GMP compliant facility in Vorarlberg, Austria. HANAFSAN CBD cosmetic products are already certified for sale in Germany without a prescription of a doctor.
HANAFSAN CBD oils are produced from high-quality full-spectrum hemp extracts produced from certified EU hemp varieties and formulated according to EU pharmaceutical standards into cold-pressed organic hemp seed oil. HANAFSAN CBD creams use hemp extract from the leaves of approved EU hemp varieties and formulate with a cold-pressed organic hemp seed oil, shea butter and aloe vera, which can produce a revitalizing and hydrating effect. Dr. Feurstein Medical Hemp Extract Oil for Oil Pulling is a dentist recommended product that can support dental and oral health issues.
Click here to view HANAFSAN’s products: https://www.hanafsan.com/cbd-produkte/
Starting mid-May 2021, AMP sales team will offer hemp extract CBD oils for cosmetic appliances in 5%, 10%, 15% CBD concentration and hemp extract creams in 0.3% and 3% CBD concentration available in different volume sizes and “Dr. Feurstein Medical Hemp Extract Oil for Oil Pulling” in 0.3% CBD concentration.
Dr. Daniel Feurstein, CEO and Founder of HANAFSAN, said, “With the declassification of CBD as a narcotic in the EU, we wanted a strong German partner to represent our brand, the largest market in Europe. AMP’s sales team have been trained on the benefits of medical cannabis and cover all the major sales regions in Germany.”
Dr. Stefan Feuerstein, President and Director of AMP, commented, “We just completed our sales training session where representatives from HANAFSAN presented their products to our team. We expect sales of CBD medical and consumer products to grow exponentially in Germany beginning this year. We wanted our first certified CBD product to be a high-quality product for our sales team to offer to our pharmacist customers.”
About HANAFSAN by Dr. Feurstein
HANAFSAN is a brand of Dr. Feurstein Medical Hemp GmbH, an innovative and scientifically focused producer of certified CBD hemp products and organic hemp foods cultivated and manufactured in the EU. The pharmaceutical company, with its office in Altach, Austria has HANAFSAN Stores in Götzis, Austria and Konstanz, Germany and a warehouse in Zurich, Switzerland. The products are Austria Bio Garantie certified and hold the certification mark of the Austrian Economic Chamber “cosmetic producer with certified know-how”. The translation of HANAFSAN’s name is: HANAF, which means hemp in Old High German and SAN means “to heal” in Latin.
For more information, please visit www.hanafsan.com.
AMP Alternative Medical Products Inc. (formerly AMP German Cannabis Group Inc.) is a pharmaceutical narcotic supplier of medical cannabis to German pharmacies with offices in Erfurt and Berlin, Germany. AMP operates in accordance with the German Narcotic Drug Act (BtMG) and with the Free State of Thuringia, ensuring medical cannabis products imported by AMP from around the world and sold in Germany meet the European Union – Good Manufacturing Practice (EU-GMP) standard. AMP’s nationwide sales team represents medical and commercial cannabis product brands from Aphria, Bedrocan, Little Green Pharma and HANAFSAN.
The AMP Roundtable Series discusses issues about medical cannabis in Germany and is available as a podcast and video. In Episode #2, “Politics and Medical Cannabis in Germany” Dr. Wieland Schinnenburg, MdB (FDP), provides an up-to-date overview of the political issues and challenges facing the medical cannabis industry in Germany. Learn more at www.amp-eu.de/roundtable.
To learn more about the European cannabis industry, download AMP’s sponsored report by Prohibition Partners; https://prohibitionpartners.com/reports/the-european-cannabis-report-6th-edition/
For more information, please visit www.amp-eu.com.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accept responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements that are based on the Company’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans and milestones and the timing thereof. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements do not guarantee future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.
SOURCE AMP Alternative Medical Products Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2021/12/c1781.html